Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Application for quotation of securities – RAD

Thursday, June 12, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has announced the initiation of a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01), following IND approval from the US FDA. The company has also provided positive updates across four clinical programs. This development marks a significant step forward for Radiopharm in its clinical endeavors.
Price reaction · baseline $5.3 (2025-06-12T19:13:00.000Z) · hit during market hours · 1 other RADX headline(s) in the window, move may be shared
day 0 close · peak
+0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has received IND approval from the US FDA.
  • The company is initiating a Phase I therapeutic clinical study.
  • Positive updates across four clinical programs indicate progress.

Full Press Release Details

• Announcements
• Appendix 2A
• June 12, 2025
Loading Viewer…

More Announcements & Updates

• Announcements , Updates
• October 20, 2025
• Updates
• December 14, 2023
• Announcements
• November 22, 2022
• Announcements
• April 12, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the purpose of the Phase I study for BetaBart?

The Phase I study aims to target B7H3 using the product BetaBart (RV-01).

When did Radiopharm receive FDA approval?

Radiopharm received IND approval from the US FDA to initiate the study.

What updates has Radiopharm provided?

Radiopharm has provided positive updates across four clinical programs.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic product developed by Radiopharm Theranostics.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm BetaBart Phase I FDA approval clinical study
Last updated: Jun 12, 2025